Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,162,606
  • Shares Outstanding, K 100,363
  • Annual Sales, $ 2,861 M
  • Annual Income, $ 478,600 K
  • EBIT $ 619 M
  • EBITDA $ 637 M
  • 60-Month Beta 0.31
  • Price/Sales 4.59
  • Price/Cash Flow 26.13
  • Price/Book 4.01

Options Overview Details

View History
  • Implied Volatility 30.39% (+0.69%)
  • Historical Volatility 38.14%
  • IV Percentile 22%
  • IV Rank 17.21%
  • IV High 69.08% on 04/08/25
  • IV Low 22.35% on 08/29/25
  • Expected Move (DTE 21) 10.14 (7.76%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 4
  • Volume Avg (30-Day) 408
  • Put/Call OI Ratio 1.53
  • Today's Open Interest 8,868
  • Open Int (30-Day) 9,602
  • Expected Range 120.50 to 140.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.27
  • Number of Estimates 5
  • High Estimate 1.78
  • Low Estimate 1.01
  • Prior Year 0.08
  • Growth Rate Est. (year over year) +1,487.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
122.14 +6.96%
on 02/12/26
142.82 -8.53%
on 02/10/26
-3.87 (-2.88%)
since 01/26/26
3-Month
122.14 +6.96%
on 02/12/26
160.18 -18.44%
on 12/08/25
-20.94 (-13.81%)
since 11/26/25
52-Week
84.23 +55.10%
on 04/09/25
160.18 -18.44%
on 12/08/25
+13.05 (+11.10%)
since 02/26/25

Most Recent Stories

More News
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

SAN DIEGO , Feb. 24, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:

NBIX : 130.64 (-0.39%)
Neurocrine: Q4 Earnings Snapshot

Neurocrine: Q4 Earnings Snapshot

NBIX : 130.64 (-0.39%)
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026

Total Fourth-Quarter and Full-Year 2025 Net Product Sales of $798.3 Million and $2.83 Billion , Representing Year-Over-Year Growth of 29% and 22%, Respectively

NBIX : 130.64 (-0.39%)
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia

SAN DIEGO , Jan. 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults...

NBIX : 130.64 (-0.39%)
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results

Conference Call and Webcast Scheduled for Wednesday, February 11

NBIX : 130.64 (-0.39%)
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR

SAN DIEGO , Jan. 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first head-to-head data comparing vesicular monoamine transporter...

NBIX : 130.64 (-0.39%)
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAN DIEGO , Jan. 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 44 th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Monday, January...

NBIX : 130.64 (-0.39%)
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy

SAN DIEGO , Dec. 22, 2025 /PRNewswire/ --  Neurocrine Biosciences, Inc.  (Nasdaq: NBIX) today announced that its Phase 3 KINECT ® -DCP study evaluating the efficacy, safety, and tolerability...

NBIX : 130.64 (-0.39%)
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology

Provided Update on R&D Engine Now On Track to Deliver Multiple First- and Best-in-Class Medicines, Positioning Company for Long-Term Value Creation Across Therapeutic Modalities

NBIX : 130.64 (-0.39%)
Neurocrine Biosciences to Host R&D Day on December 16

SAN DIEGO , Dec. 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will hold its 2025 R&D Day on Tuesday, December 16, 2025, at 12:00 p.m. Eastern Time (9:00...

NBIX : 130.64 (-0.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

3rd Resistance Point 135.51
2nd Resistance Point 133.85
1st Resistance Point 132.25
Last Price 130.64
1st Support Level 128.98
2nd Support Level 127.32
3rd Support Level 125.72

See More

52-Week High 160.18
Fibonacci 61.8% 131.17
Last Price 130.64
Fibonacci 50% 122.21
Fibonacci 38.2% 113.24
52-Week Low 84.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar